Summary & Overview
HCPCS Level II J1809: Fosdenopterin Injection, 0.1 mg
HCPCS Level II code J1809 denotes the injectable medication fosdenopterin in a 0.1 mg unit. As a specific product-level code for a specialty injectable, J1809 is relevant to clinicians, billing teams, specialty pharmacies, and payers because it drives claims detail for high-cost or rare-disease therapies and informs benefit design, prior authorization requirements, and site-of-care decisions. Nationally, accurate use of J1809 supports consistent coverage determinations and payment processing for this therapy.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication provides a concise view of clinical context for fosdenopterin injections, expected service settings (outpatient infusion/clinic, physician office, or specialty pharmacy administration), and implications for billing workflows.
Readers will learn: the clinical and service-level meaning of J1809, typical sites of service where the code applies, how major payers and Medicare approach this type of HCPCS-coded injectable at a high level, and where to look for policy or coverage updates relevant to specialty injectables. Data not provided in the input (such as associated ICD-10 diagnoses, related codes, and payer-specific coverage rules) is noted where applicable.
Billing Code Overview
HCPCS Level II code J1809 represents an injection of fosdenopterin, packaged in a dose of 0.1 mg. This code is used to report administration of the specified biologic or specialty medication formulation.
Service Type: Medication administration / Injectable therapy
Typical Site of Service: Outpatient infusion or injection clinic, physician office, or specialty pharmacy-administered setting
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A pediatric patient with molybdenum cofactor deficiency or xanthine oxidase–related metabolic enzyme deficiency presents with neurologic deterioration and biochemical evidence consistent with a disorder responsive to fosdenopterin therapy. The patient is evaluated in a specialty metabolic clinic and by a pediatric neurologist. After genetic confirmation and authorization for medication, fosdenopterin (J1809, injection, 0.1 mg) is prepared by an inpatient or outpatient infusion center pharmacy and administered by an experienced infusion nurse. Typical workflow steps include medication order verification, compounding under aseptic technique, baseline vital signs and allergy verification, administration via subcutaneous or intravenous route per product labeling and institutional protocol, monitoring for adverse reactions during and after dose, documentation of lot number and amount administered, and billing using J1809 units corresponding to the milligram dose delivered. Common sites of service are outpatient infusion centers, hospital inpatient beds, and specialty pediatric clinics with infusion capability.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default / No modifier | Use when no special modifier applies to the service |